Cardiomyocyte Cell Populations

• US 20100158872A1
• Filed: 06/22/2006
• Published: 06/24/2010
• Est. Priority Date: 06/23/2005
• Status: Abandoned Application

• Current Assignee: Icahn School of Medicine at Mount Sinai
• Original Assignee: Mount Sinai School of Medicine of New York University
• Inventors: Chen, Chang-Yi, Keller, Gordon M.
• Application Number:
  US11/993,688
• Publication Number:
  US 20100158872A1
• Time in Patent Office: Days
• US Class Current: 424/93.700
• CPC Class Codes: A61P 43/00 Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
• CPC Class Codes: A61P 9/00 Drugs for disorders of the cardiovascular system
• CPC Class Codes: A61P 9/04 Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
• CPC Class Codes: C12N 2501/42 Notch; Delta; Jagged; Serrate
• CPC Class Codes: C12N 2502/1394 Bone marrow stromal cells; whole marrow
• CPC Class Codes: C12N 2506/02 from embryonic cells
• CPC Class Codes: C12N 5/0647 Haematopoietic stem cells; Uncommitted or multipotent progenitors
• CPC Class Codes: C12N 5/0657 Cardiomyocytes; Heart cells
• CPC Class Codes: C12N 5/0692 Stem cells; Progenitor cells; Precursor cells

Abstract

The present invention provides methods for inducing the differentiation of cardiac progenitor cells and cell populations produced by the methods of the invention. The invention further provides a method of screening for agents that affect cardiomyocytes, and a method of cardiomyocyte replacement therapy.

Claims

1. A method of inducing differentiation of cardiac cells from embryonic stem (ES) cells comprising culturing ES cells under conditions sufficient for formation of embryoid bodies (EBs), culturing the EBs under conditions sufficient for differentiation to hemangioblast/pre-erythroid cells, and isolating and reaggregating the hemangioblast/pre-erythroid cells in the presence of activated Notch to provide cardiac progenitor cells.

2. The method of claim 1 further comprising culturing said cardiac progenitor cells in the absence of Notch and under conditions sufficient for differentiation to cardiomyocytes.

3. The method of claim 1 wherein activated Notch is provided by adding a Notch ligand.

4. The method of claim 3 wherein the Notch ligand is selected from the group consisting of Delta-like-1, Delta-like-2, Delta-like-3, Jagged1 and Jagged2.

5. The method of claim 1 wherein the ES cells contain a nucleic acid encoding Notch operably linked to a regulatory element that controls inducible expression.

6. The method of claim 5 wherein the nucleic acid encodes the intracellular domain of Notch.

7. The method of claim 1 wherein Notch is Notch1, Notch2, Notch3 or Notch4.

8. The method of claim 1 wherein Notch is Notch4.

9. The method of claim 1 wherein Notch is the intracellular domain of Notch4.

10. The method of claim 1 wherein activated Notch is provided by inducing the expression of a nucleic acid encoding Notch in the hemangioblast/pre-erythroid cells.

11. The method of claim 1 wherein the ES cells are mouse ES cells or primate ES cells.

12. The method of claim 1 wherein the ES cells are human ES cells.

13. The method of claim 1 wherein the ES cells are Notch4-ES cells.

14. The method of claim 2 further comprising culturing the cardiomyocytes in the absence of Notch.

15. The method of claim 1 wherein the EBs are cultured in serum for about 2.5 to 4.5 days.

16. The method of claim 1 wherein the EBs are cultured in serum for about 3 days.

17. The method of claim 1 wherein the reaggregated hemangioblast/pre-erythroid cells are cultured in the presence of activated Notch for about 12-48 hours.

18. The method of claim 1 wherein the reaggregated hemangioblast/pre-erythroid cells are cultured in the presence of Notch for about 24 hours.

19. The method of claim 1 wherein the reaggregated hemangioblast/pre-erythroid cells are cultured in serum-free conditions.

21. A cell population produced by the method of claim 2 comprising at least about 10% cardiomyocytes.

22. A cell population of claim 21 comprising at least about 50% cardiomyocytes.

23. A cell population of claim 21 comprising at least about 60% cardiomyocytes.

24. A method of screening for an agent that has an effect on cardiomyocytes comprising contacting cardiomyocytes produced by the method of claim 2 with a candidate agent and assaying for an effect on the cardiomyocytes, wherein the presence of an effect is indicative of the identification of an agent that has an effect on cardiomyocytes.

25. A method of cardiomyocyte replacement therapy comprising administering to a subject in need of such treatment a composition comprising cardiomyocytes produced by the method of claim 2.

26. The method of claim 25 wherein the composition is administered by injection or implantation.

20. A method of inducing differentiation of cardiac cells from embryonic stem (ES) cells comprising culturing ES cells under conditions sufficient to form embryoid bodies (EBs), wherein the ES cells contain a nucleic acid encoding the active intracellular domain of Notch4 operably linked to a regulatory element that controls inducible expression by an inducer;

culturing the EBs in serum for about 3 days;

isolating Flk-1+ cells;

reaggregating the Flk-1⁺ cells in the presence of the inducer for about 24 hours to provide cardiac progenitor cells; and

culturing said cardiac progenitor cells in the absence of the inducer in serum free medium to provide cardiomyocytes.

27. A method of inhibiting the differentiation of cardiac cells from embryonic stem (ES) cells comprising culturing ES cells under conditions sufficient for formation of erythroid bodies (EBs), culturing the EBs under conditions sufficient for differentiation to Bry⁺/Flk-1⁻

cells, isolating Bry⁺/Flk-1⁻

cells and reaggregating the Bry⁺/Flk-1⁻

cells in the presence of an inhibitor of Notch.

28. The method of claim 27 wherein the inhibitor of Notch is γ

-secretase inhibitor X.